Vertex and crispr therapeutics announce us fda approval of casgevy™ (exagamglogene autotemcel) for the treatment of sickle cell disease

Boston & zug, switzerland--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) and crispr therapeutics (nasdaq: crsp) announced today that the u.s. food and drug administration (fda) has approved casgevy™ (exagamglogene autotemcel [exa-cel]), a crispr/cas9 genome-edited cell therapy, for the treatment of sickle cell disease (scd) in patients 12 years and older with recurrent vaso-occlusive crises (vocs). this approval means that for the first time, approximately 16,000 patients.
VRTX Ratings Summary
VRTX Quant Ranking